Hello and welcome to the details of WHO set to back weight-loss drugs for adults worldwide, seeks affordability solutions and now with the details
Nevin Al Sukari - Sana'a - A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and boxes of Wegovy, made by Novo Nordisk. — Reuters pic
LONDON, May 1 — The World Health Organisation plans to officially back the use of weight-loss drugs to treat obesity in adults for the first time, a memo reviewed by Reuters today shows, marking a shift in its approach to treating the global health problem.
The UN agency also called for strategies to improve access to the treatment in low- and middle-income countries.
More than a billion people now have obesity worldwide, according to the WHO, and around 70 per cent of them live in low and middle-income countries, the World Bank estimates.
The wildly popular obesity drugs — Wegovy developed by Novo Nordisk and Zepbound by Eli Lilly — are known as GLP-1 receptor agonists, which mimic the activity of a hormone that slows digestion and helps people feel full for longer. In clinical trials, people lost 15 per cent to 20 per cent of their body weight, depending on the drug.
The drugs have been launched in the United States and other high-income countries like Germany and Britain.
But they can cost over US$1,000 a month, and studies suggest people may have to take the drugs for the rest of their lives to keep the weight off.
The WHO, Eli Lilly and Novo Nordisk were not immediately available for comment.
The WHO’s conditional recommendation will be officially released in August, as part of new guidelines on treating obesity. It is also working on separate guidelines for children and adolescents.
Separately, WHO experts will also meet next week to decide whether to include the GLP-1 drugs in the agency’s essential medicines list — both to treat obesity and type 2 diabetes.
The WHO’s essential medicines list is a catalogue of the drugs that should be available in all functioning health systems, and it can help make drugs more widely available in poorer countries, as experts say happened in 2002 when HIV drugs were included.
In 2023, the experts decided against adding obesity drugs to the list, with WHO saying more evidence was needed on their long-term clinical benefit.
However, in the new memo recommending their use as a treatment, the agency says it supports including them on the list this time round.
Still, the WHO also raises concerns over the cost of the drugs and calls for longer-term studies on cost-effectiveness “across all settings, including LMICs” (low- and middle-income countries).
“The same mechanisms that are used in large-scale medicine access programmes may need to be adopted,” to improve access, the WHO adds, such as tiered pricing or pooled procurement.
But it also notes that the active ingredient in one of the newer drugs, semaglutide — used in Novo’s Wegovy — comes off patent in some markets next year.
Several companies are planning to launch cheaper generic versions of the drugs then. Liraglutide, the active ingredient in the older generation of drugs, is already available as a lower-cost generic drug, with products approved in the US and Europe, the memo adds. — Reuters
These were the details of the news WHO set to back weight-loss drugs for adults worldwide, seeks affordability solutions for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at Malay Mail and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.
